Andere Sprachen Soleno Therapeutics, Inc.

Aktien

A3DS0P

US8342033094

SLNO

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 01.05.2024			% 5 Tage	% 1. Jan.
47,54 ^USD	+6,45 %		+20,84 %	+18,11 %

29.04.	Aktien von Soleno Therapeutics steigen, nachdem die FDA einen Durchbruch für die Behandlung des Prader-Willi-Syndroms festgestellt hat	MT
29.04.	Soleno Therapeutics, Inc. erhält von der U.S. FDA den Status eines Therapiedurchbruchs für DCCR (Diazoxid-Cholin) Tabletten mit verlängerter Wirkstofffreisetzung bei Prader-Willi-Syndrom (PWS)	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Soleno Therapeutics Announces Peer-Reviewed Publication of Data Comparing DCCR Treatment to the Natural History of Prader-Willi Syndrome	30.04.
Soleno Therapeutics' Shares Jump After FDA Grants Breakthrough Designation for Prader-Willi Syndrome Treatment	29.04.
Soleno Therapeutics Gets Breakthrough Therapy Designation for Diazoxide Choline	29.04.
Soleno Therapeutics Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (PWS)	29.04.
Soleno Therapeutics, Inc. Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome	29.04.
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4) - April 19, 2024	22.04.
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	19.04.
Soleno Therapeutics Insider Sold Shares Worth $784,645, According to a Recent SEC Filing	04.04.
North American Morning Briefing : Investors -2-	18.03.
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	08.03.
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results	06.03.
Soleno Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	06.03.
Soleno Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	06.03.
Soleno Therapeutics : March 2024 Corporate Presentation	04.03.
Soleno Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference	22.02.
Soleno Therapeutics to Present at Upcoming February Investor Conferences	01.02.
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	29.01.
Soleno Therapeutics Names Meredith Manning as Chief Commercial Officer	24.01.
Soleno Therapeutics Strengthens Leadership Team with Key Appointments	24.01.
Soleno Therapeutics Strengthens Leadership Team with Key Appointments	24.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Soleno Therapeutics, Inc.

Aktien

A3DS0P

US8342033094

SLNO

Andere Sprachen

Filter